青霉素过敏反应患者行全髋与全膝关节置换术围手术期使用头孢唑林的安全性
214例有青霉素过敏反应记录并使用头孢唑林的患者中仅1例出现快速反应团队激活或肾上腺素使用,无统计学显著性;万古霉素使用与快速反应团队激活或肾上腺素使用显著相关。
要点
- 214例有青霉素过敏反应记录并使用头孢唑林的患者中仅1例出现快速反应团队激活或肾上腺素使用,无统计学显著性。
- 全部患者中万古霉素使用与快速反应团队激活或肾上腺素使用相关,OR为7.2(95%CI 4.4至11.7)。
- 无青霉素过敏记录亚组中万古霉素使用与快速反应团队激活或肾上腺素使用相关,OR为11.6(95%CI 6.9至19.7)。
核心结论
- 有青霉素过敏反应记录的患者使用头孢唑林未显著增加过敏反应或临床不稳定风险。
- 这些发现支持头孢唑林在有青霉素过敏反应患者中的安全性,可能减少对效果较差二线抗生素的依赖。
研究设计与样本
- 患者分为青霉素过敏反应组、青霉素非过敏反应组和非青霉素过敏对照组。
- 记录围手术期抗生素使用、肾上腺素给药和快速反应团队激活作为过敏反应标志物;统计分析包括逻辑回归、卡方检验和Fisher精确检验。
主要发现
- 214例有青霉素过敏反应记录并使用头孢唑林的患者中,仅1例出现快速反应团队激活或肾上腺素使用,无统计学显著性。
- 全部患者中万古霉素使用与快速反应团队激活或肾上腺素使用显著相关,OR为7.2(95%CI 4.4至11.7)。
- 无青霉素过敏记录亚组中万古霉素使用与快速反应团队激活或肾上腺素使用显著相关,OR为11.6(95%CI 6.9至19.7)。
临床怎么用
- 2022年本研究中心实施方案,允许所有患者包括有青霉素过敏者使用头孢唑林,但记录有严重非IgE介导反应者除外。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cefazolin, a first-generation cephalosporin, is the preferred antibiotic for prophylaxis in elective primary total hip and knee arthroplasties (THAs and TKAs). While most of its chemical structure differs from penicillin (PCN), its shared beta-lactam ring has historically raised concerns about cross-reactivity in patients who have with reported PCN allergies. However, studies suggest that patients who report a PCN allergy have a 50% increased odds of surgical site infection, often due to receiving second-line perioperative antibiotics. In 2022, our institution implemented a protocol allowing cefazolin administration for all patients, including those who have PCN allergies, except in cases of documented severe non-IgE-mediated reactions. This study analyzed the incidence of anaphylaxis to cefazolin in patients who have documented anaphylactic PCN allergies undergoing primary THA or TKA. METHODS: We conducted a retrospective cross-sectional study of 8,456 patients who underwent THA or TKA at a tertiary academic center between 2008 and 2024. Patients were grouped as anaphylactic PCN allergic, nonanaphylactic PCN allergic, and a non-PCN allergy control. Along with perioperative antibiotic use, epinephrine (EPI) administration and rapid response team (RRT) activation were recorded as markers of anaphylaxis. Statistical analysis included logistic regression, Chi-square, and Fisher's exact tests. RESULTS: Among 214 patients who had documented PCN anaphylaxis who received cefazolin, only one patient experienced RRT or EPI, which was not statistically significant. In all patients and the subgroup without documented PCN allergies, vancomycin use was significantly associated with RRT or EPI in these groups, with odds ratios of 7.2 (95% CI [confidence interval]: 4.4 to 11.7) and 11.6 (95% CI: 6.9 to 19.7), respectively. CONCLUSIONS: Cefazolin administration did not significantly increase the risk of anaphylaxis or clinical instability in patients who had documented PCN anaphylaxis. These findings support the safety of cefazolin in anaphylactic PCN-allergic patients, potentially reducing the reliance on less effective second-line antibiotics.
引用
- Wagner M, Patel NB, Michaels R, et al. Safety of Perioperative Cefazolin in Penicillin-Anaphylactic Patients for Total Hip and Knee Arthroplasty. J Arthroplasty. 2025. PMID: 40517967. doi:10.1016/j.arth.2025.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。